The Radcliffe Cardiology Podcast

NVM Cardiology Meeting Reflections: TCT 25 Wrap Up

In this Redcliffe Cardiology NVM reflections episode, Prof Nicolas Van Mieghem cuts through the noise from TCT 2025. Tune in to hear what the SELUTION trials mean for drug-coated balloons in de novo disease and ISR, why cost and sizing matter in calcium modification, how PE thrombectomy stacks up against anticoagulation alone, and what 7-year PARTNER 3 and 10-year NOBLE data signal for TAVR and left main PCI. Practical takeaways you can use on your next case. Drug-coated balloons (DCB): SELUTION-ISR and the large SOLUTION DeNovo RCT show non-inferiority vs contemporary care,with ~80% of DCB cases avoiding a stent. How to size, when to escalate to DES, and why 5-year data will be decisive. We also contrast these results with CAGE-FREE-1 three-year outcomes and discuss “not all DCBs are created equal.” Calcium strategies: SHORT-CUT and VICTORY pit cutting/high-pressure balloons against intravascular lithotripsy. Similar luminal results—but very different costs and workflow. We outline a toolbox and imaging-first algorithm for nodular/annular calcium and where atherectomy still fits. Pulmonary embolism: STORM-PE shows catheter thrombectomy on top of anticoagulation cuts RV/LV ratio fast along with real-world procedure times, blood loss, and complications you should counsel up front. Valves & MR: PARTNER 3 at 7 years TAVR vs surgery outcomes remain similar with reassuring valve durability; mild PVL not tied to mortality. ENCIRCLE (Sapien M3 TMVR) shows strong MR elimination but flags stroke and leaflet thrombosis prompting a rethink of antithrombotic strategy. Coronary trials: NOBLE 10-year left main results, PROCTOR (native CTO vs SVG PCI), I-MODERN (iFR-guided complete revasc vs deferred CMR), iCABG (physiology-guided grafting), INFINITY SWEDEHEART (bioadaptor stent signals), and ANDES (post-LAAO DOAC vs DAPT). Expect pragmatic thresholds, device selection tips, and critical review of the latest evidence with Prof Nicolas Van Mieghem.

TCT 25 Structural Interventions Highlights: Real-World Outcomes and Latest Trial Updates

At TCT 2025, Dr Nadira Hamid (Minneapolis Heart Institute, US) and Dr. Rahul P. Sharma (Stanford University, US) review the late-breaking trial data shaping the future of structural heart disease. The discussion highlights real-world results from TRISCEND and TRILUMINATE in tricuspid disease, 7-year PARTNER 3 durability outcomes in TAVR, national prevalence insights from the PREVUE-VALVE study, and new frontiers in mitral intervention with SUMMIT MAC. Together, they examine what the evidence means for safety, durability, patient selection, and clinical adoption. 01:05 – Tricuspid Therapies Late-breaking data from Triluminate (TriClip) and Tricend/Evoke: real-world outcomes, bleeding reduction, pacemaker trends, and patient selection. 06:40 – Aortic Valve Durability PARTNER 7-year outcomes: TAVR vs. SAVR, valve performance over time, implications for younger/lower-risk patients, and evolving device technology. 12:55 – Valvular Disease Prevalence Insights from the PREVUE-VALVE: first nationwide prevalence data, under-treatment of severe disease, and role of AI in early detection. 17:30 – Mitral Valve Advances Landmark trials: SUMMIT Trial (MAC population) and first-in-human Sapien M3 transseptal TMVR. Key outcomes, screen failure rates, and implications for clinical adoption. 24:50 – Future of Structural Heart Interventions Patient-first approach, expanding treatment options, and importance of durability and early diagnosis. For more content from TCT 2025 head to the Late-breaking Science Video Collection. Editor: Mirjam Boros Videographer: Tom Green and Dan Brent Support: This is an independent video produced by Radcliffe Cardiology.

View from the Thoraxcenter: ESC 25 Late-breaking Science Wrap-Up

Explore ESC 25 Top Trials with Insights from the Thoraxcenter! Join Prof Nicolas Van Mieghem and Dr Joost Daemen from Erasmus MC, Rotterdam, for an engaging and critical analysis of the latest trials unveiled at ESC 2025. In this comprehensive ESC wrap-up, interventional experts examine the most significant trials, providing valuable insights into their impact on current practices and future research directions. 00:15 - DOUBLE-CHOICE 04:43 - VANTAGE 07:44 - VICTOR and VICTORIA 11:29 - DIGIT-HF 14:22 - DAPA ACT HF-TIMI 68 16:55 - BETAMI-DANBLOCK and REBOOT-CNIC 22:13 - REFINE-ICD 25:34 - OPTION-STEMI 30:40 - DUAL-ACS 33:05 - NEO-MINDSET 35:58 - TARGET-FIRST 38:54 - OUTREACH 41:50 - FIRE 42:46 - AI-Gatekeeper 45:13 - POTCAST

View from the Thoraxcenter: What's Hot at ESC 25?

Expert interventionalists, Prof Nicolas Van Mieghem and Dr Joost Daemen (Thoraxcenter, Erasmus MC, Rotterdam, NL) discuss the most anticipated hot line studies to be unveiled at ESC Congress 2025. Tune in for their in-depth analysis to get ahead of the curve. ESC Congress 2025 Hot Line Trials Discussed: 00:25 - DOUBLE-CHOICE 03:03 - VANTAGE 05:03 - VICTOR 06:28 - VICTORIA 07:58 - DIGIT HF 10:19 DAPA ACT HF-TIMI 68 12:35 REBOOT-CNIC 14:07 BETAMI DANBLOCK 16:03 REFINE ICD 18:05 OPTION STEMI 20:43 DUAL ACS 22:46 NEO MINDSET 24:53 TARGET FIRST 26:59 OUTREACH 29:29 FIRE 31:40 AI GATEKEEPER 22:42 LAA CLOSURE Stay tuned for Radcliffe Cardiology’s in-depth coverage of these and other pivotal trials from ESC Congress 2025.

Women in Cardiology: Small in Number, Large in Impact with Dr Roxana Mehran

Women in Cardiology: Small in Number, Large in Impact with Dr Roxana Mehran by The Radcliffe Cardiology Podcast